MediWound
MDWD
MediWound (MDWD) news
Recent news
MEDIWOUND FY 2026 revenue guidance reaffirmed at $24-26M
AInvest Wire · May 27, 2026MediWound: FDA accepted for review supplement to Nexobrid Bla.
MediWound: FDA accepted for review supplement to Nexobrid Bla. MediWound, a biotechnology company specializing in tissue repair and regeneration, has recently received positive news from the US Food and Drug Administration (FDA). The FDA has accepted MediWound's re-submitted Biologics License…
AInvest Wire · Jan 9, 2024Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.